Should Radiation Dose Be Personalized in Patients With Localized NSCLC and Actionable Genetic Alterations? Insight From a Multicenter Real-World Study

Objectives: Radiation therapy (RT) is central to the management of unresectable stage I to III NSCLC. However, the impact of actionable genetic driver alterations (AGAs) on locoregional control (LRC) from RT remains uncertain. A retrospective, multicenter real-world study was undertaken to determine...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Salman Ashraf, MB BCh BAO, Madeha Khan, FRCR, Nada Naguib, FRCR, Robert Rulach, FRCR, PhD, Katharine Welsh, FRCR, Rebecca Carozzi, MRCP, Ashley Horne, FRCR, Amelia Payne, MRCP, MRes, Sarah Bowen Jones, FRCR, Mary Denholm, FRCR, Georgia Stewart, MB MSc, Ahmed Bedair, FRCR, Colin R. Lindsay, MRCP, PhD, Stephen Harrow, FRCR, PhD, Corinne Faivre-Finn, FRCR, PhD, Jonathan McAleese, FRCR, Gerard G. Hanna, FRCR, PhD, Allan Hackshaw, PhD, Fiona McDonald, FRCR, MD, Gerard M. Walls, FRCR, PhD
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-04-01
סדרה:	JTO Clinical and Research Reports
נושאים:	Non-small cell lung cancer Radiation therapy Actionable genetic alterations Mutations Locoregional control
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2666364324001449
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!